• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Amgen to Acquire Five Prime Therapeutics for $1.9B

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Reed-Lane Facility Virtual Tour

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    WuXi AppTec Completes OXGENE Acquisition

    Trends in Solid Oral Dosage Delivery
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Strata Oncology Unveils Strata PATH Trial
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Alcami

    Reed-Lane

    Baxter BioPharma Solutions

    Cytovance Biologics
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Syngene

    Cytovance Biologics

    Reed-Lane

    Almac Group
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Economics of In-House Buffer Preparation

    Evaluating the cost effectiveness of keeping basic ops in-house

    Related CONTENT
    • Bora Pharmaceuticals
    • Dr. Reddy’s Expands Biomanufacturing Capabilities
    • Current Trends in Analytical Testing
    • CMOs & Biosimilars Mfg. in the U.S.
    • CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges
    Eric S. Langer, BioPlan Associates09.08.16
    Buffer preparation, like culture media preparation, is a task classically performed in-house by bioprocessing facilities. Until recently, preparation of these working fluids has generally been viewed as a “core” operation to be kept in-house and not outsourced.  However, some biomanufacturers have been questioning and evaluating the cost effectiveness of keeping relatively basic operations like buffer prep in-house, when suppliers are beginning to offer these as outsourced materials. BioPlan Associates conducted a follow-on study to our analysis in 2014 to assess the cost-effectiveness of buffer preparation done in-house. These data can be used to evaluate outsourcing options.

    Increasingly, these classically core powder hydration/prep operations are candidates for outsourcing as biomanufacturers seek to do more with fewer staff at lower costs. Bioprocessing facilities have generally taken an in-house platform approach to buffer—and media—preparation, using common equipment. 

    But there are total facility costs associated with buffer preparation that differ between facility types. We wanted to assess how these costs vary based on facility size and bioprocessing scales. And how costs of buffer prep using stainless steel compare to use of single-use equipment or hybrid. 

    In our earlier study of bioprocessing fluids outsourcing we found that nearly half of the respondents (47%), indicated that large-scale media and buffer prep outsourcing was an option they would actively consider. Thus, even core bioprocessing tasks, such as buffer prep, are becoming candidates for outsourcing. In some cases, purchase and delivery of buffer—and culture media—fluid prepared remotely by buffer fluid vendors or hired CMOs may be preferred and potentially more cost-effective than in-house preparation. Not unexpectedly, this tends to more be the case for smaller facilities, facilities doing intermittent bioprocessing. While in-house prep generally remains the pattern at larger commercial scales. Shipping of fluids can very often be the main cost in purchase of pre-prepared bioprocessing fluids. 

    But with buffer prep as with other operations, there are other factors involved beside materials and other direct/variable costs. These are captured in the model, such as overhead; allocated facility support services like administrative, and validation; costs of depreciation, etc. In addition, other intangible factors can make outsourcing more attractive. These include aspects like:
    • Potentially higher quality materials delivered from suppliers;
    • Ability to re-allocate production space from buffer prep to bioreactor capacity (utilization of classified space);
    • Speed of development (often more important than costs);
    • Regulatory compliance and documentation (absolute requirements);
    • Rapid process turnover;
    • Efficient use of staff;
    • Demands for flexible and lean operations;
    • Inventory management and warehousing;
    • Space availability;
    • Need for training; and
    • Demands for bioprocessing sterility.
    The recent study did not include consideration of these aspects, rather solely concerned itself with total in-house buffer prep costs.

    Study methodology
    To answer these questions, we developed a buffer costs preparation model based on prior research and on financial and cost inputs from industry segment experts. From this we developed a comparative buffer prep costs model (spreadsheet). We then performed a series of in-depth interviews collecting information from bioprocessing professionals that had calculated their in-house costs for buffer preparation. From this we developed a buffer prep costs model. We interviewed 10 industry staff for this project, to update cost data from 32 relevant industry end-users performed in 2014.1

    For this recent buffer costs modeling effort, expert bioprocessing professionals having calculated their in-house costs for buffer preparation, were interviewed to collect their costs estimation data. Rather than collecting only bottom line cost conclusions, interviews concentrated on trying to understand and consistently record individual cost component. Although few interviewees used the same methodologies for their internal cost accounting, we were able to estimate cost-per-liter data to help with consistency.

    Table I presents the types of buffer-related cost categories discussed in interviews. These headings may be useful as a checklist to develop buffers-related cost estimate data. As noted, a potential weakness with interviewee-collected cost estimate data is that there are no industry-accepted methods for determining and allocating bioprocessing task-related cost parameter. In many cases, obtaining cost data involved estimating each cost item jointly with interviewees. For each component cost (Table I), its current average per year cost was requested or developed. For example, “Capital Facility Expenses (Buffer Prep Building, excluding Equip/HVAC),” involved total building construction cost and determining ongoing annual financial burden, e.g., by amortizing total building costs over time at 4%, and then prorating this by the estimated percentage of facility space allotted to buffers. Buffer prep-related construction costs also vary greatly, depending on the facility size and bioprocessing scale. 

    Study results
    Figure 1 shows results of averaging estimated total in-house buffer-prep costs for different size facilities. The overall average cost for in-house buffer preparation was $19.72. Note, the costs for buffer prep do not include costs related to buffer R&D, process design/development, etc.; and only buffer prep from source powders, not from fluid concentrates, was considered. The costs of in-house automated buffer prep dilution from outsourced purchased concentrates, a growing trend but still mostly used only at commercial manufacturing scales, were not considered in this study.

    As expected and shown in Figure 1, costs/L of buffers tend to decrease as facility size and bioprocessing scales increase. Estimated average costs ranged from nearly $30/L for smaller facilities, those producing <100,000 L of buffers/year, to about $11 at largest scales, >1,000,000 L/year. Figure 1 also shows, as fully expected, the total facility costs generally increasing as facility size and bioprocessing scale go up, with facilities at <100,000 L/year having annual average buffer prep costs of $2.6 million, while those at largest scales, >1,000,000 L/year, have costs averaging in multiple $10s of millions. Note, some excess buffer manufacturing capacity is generally prudent, if not critical, for bioprocessing facilities to have, but with any such unused capacity adds to operational costs. Some excess capacity is needed, because the opportunity, loss of speed, and other costs of not having some flexible excess capacity when needed, such as need to supply product launches, deal with any buffer-related bottlenecks, avoid shortages, etc. can be devastating to a product and company.

    Facility type findings
    Average annual total buffer prep costs by type of facility, whether stainless steel, single-use or hybrid systems—used for buffer prep—also varied in the study. Operating at very large scales using stainless steel systems generally provide the lowest in-house buffer prep per liter costs, with average cost for stainless steel facilities at $11.92/L, while single-use facilities average $21.80. Note that the sample size for these facilities is insufficient to address issues of scale. However, because single-use scales are typically significantly smaller, these data suggest scaling factors should also be considered. The overall average annual average total costs for buffer prep for all facilities surveyed was $8.5 million. Overall, total average costs for in-house buffer prep were higher for stainless steel facilities, $13.2 million/year, but with these facilities tending to include larger commercial manufacturing regulatory compliance and documentation, operating at much larger scale than the others. The overall average cost for single-use facilities was $5.5 million.

    The average facility fixed costs by facility size were also evaluated. Average for all facilities’ fixed costs were $4.47/L or about 22.6% of the average total cost. There is a general trend for lower fixed costs/L at larger scales, as expected. Average per liter costs are $6.77 at small scales (<100,000 L/year); but $3.08 at largest, >1,000,000 L/year scale. 

    Average annual in-house buffer prep fixed costs by facility type included fixed cost/liter for stainless steel facilities at $3.55/L; and $3.87 for single-use. 

    Average annual total variable costs by facility size generally trended lower as facility size and bioprocessing scales increase. The overall average annual variable costs were $10.67/L. Small facilities (<100,000 L/year) had average costs of $14.86/L; those at the largest facilities, >1,000,000 L/year had average costs of $4.88.
    Variable costs by facility type, not unexpectedly, showed single-use facilities as having higher costs. Overall average annual variable buffer prep costs was $10.67/L, with single-use at $12.37/L and stainless steel at $6.92/L. Stainless steel costs are expected to be lowest, with single-use system equipment needing to be purchased new for each bioprocessing run or campaign.

    There is a general trend for lower labor costs/L, i.e., higher staff productivity, as facility size and (bioprocessing scales increase. Average cost/L vary over a range about 100%, from the lowest $3.17/L at largest scales (>1,000,000 L/year) to highest at $7.54/L at small scale (<100,000 L/year).

    Conclusions
    The difference and trends with total in-house average annual buffer prep from powder costs were generally as expected. Costs per liter were lower and productivity was higher for larger and stainless steel facilities, with being larger facilities generally stainless steel—and vice versa. 

    Although the costs for outsourcing of buffer fluids preparation are generally significantly higher than for in-house preparation as expected, the intangible value of outsourced buffers may outweigh a simple cost calculation. Further, though outsourced fluids may reduce some costs, certain costs remain, including storage, staff time, regulatory filings, on-site filtration, management overhead, QA/QC lab, and other costs included in the in-house total cost calculations may also apply to externally purchased buffers. 

    References
    1. Langer, E.S., “Outsourcing Media and Buffer Prep,” Contract Pharma, Sept. 8, 2014.


    Eric S. Langer
    BioPlan Associates

    Eric S. Langer is president and managing partner at BioPlan Associates, Inc., a biotechnology and life sciences marketing research and publishing firm established in Rockville, MD in 1989. He is editor of numerous studies, including “Biopharmaceutical Technology in China,” “Advances in Large-scale Biopharmaceutical Manufacturing”, and many other industry reports.  elanger@bioplanassociates.com  301-921-5979.  www.bioplanassociates.com
    Related Searches
    • Biologics, Proteins, Vaccines
    Suggested For You
    Bora Pharmaceuticals Bora Pharmaceuticals
    Dr. Reddy’s Expands Biomanufacturing Capabilities Dr. Reddy’s Expands Biomanufacturing Capabilities
    Current Trends in Analytical Testing Current Trends in Analytical Testing
    CMOs & Biosimilars Mfg. in the U.S. CMOs & Biosimilars Mfg. in the U.S.
    CMOs Hiring Constraints:  Cell Therapy Manufacturing Expecting Future Challenges CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges
    Year-End Trends in Biopharma Contract Manufacturing Year-End Trends in Biopharma Contract Manufacturing
    Technology Trends: Disposable Vs. Stainless Steel Technology Trends: Disposable Vs. Stainless Steel
    Contract Manufacturing Budget Trends Contract Manufacturing Budget Trends
    China Vaults to the Top of U.S. Biomanufacturers’ Off-Shoring Prospects China Vaults to the Top of U.S. Biomanufacturers’ Off-Shoring Prospects
    Taking Stock of Biopharma’s Outsourcing Markets Taking Stock of Biopharma’s Outsourcing Markets
    Globalization Hits Biopharma Contract Manufacturing Globalization Hits Biopharma Contract Manufacturing
    CMOs Are Willing to Pay for More Innovation CMOs Are Willing to Pay for More Innovation
    Getting to Yes Getting to Yes
    Banging the CMO Drum
Banging the CMO Drum
    CMOs Facing Significant Capacity Constraints CMOs Facing Significant Capacity Constraints

    Related Columns

    • Biologics, Proteins, Vaccines
      Vaccines and Return-To-Normalcy

      Vaccines and Return-To-Normalcy

      Planning for a future in which COVID-19 won’t simply ‘disappear.’
      Ben Locwin, Contributing Editor 03.01.21

    • Biologics, Proteins, Vaccines
      Vaccines 2021

      Vaccines 2021

      Looking at the behavioral economics of vaccinations.
      Ben Locwin, Contributing Editor 01.27.21

    • Biologics, Proteins, Vaccines
      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      Race for the vaccines is heating up.
      Ben Locwin, Contributing Editor 09.09.20


    • Biologics, Proteins, Vaccines
      Outsourcing in China: How far can it go?

      Outsourcing in China: How far can it go?

      China’s biopharmaceutical services market is on pace to top $1 billion by 2021
      Vicky Qing Xia, BioPlan Associates 07.15.19

    • Biologics, Proteins, Vaccines | Drug Development
      The Future Is… Therapeutic

      The Future Is… Therapeutic

      As cell and gene therapies rise, so too does outsourcing
      Ben Locwin 06.13.19

    • Biologics, Proteins, Vaccines
      Innovate UK Grant Supports Viral Vector Manufacturing

      Innovate UK Grant Supports Viral Vector Manufacturing

      Cobra Biologics talks about its recently awarded $3.4 million capital infrastructure investment
      Betsy Louda, Associate Editor 04.10.18


    • Biologics, Proteins, Vaccines | Injectables
      A World of Innovation

      A World of Innovation

      The importance of innovation in the injectable business and the hurdles a CDMO faces
      Claudia Roth, Vetter Pharma-Fertigung GmbH & Co. KG 11.07.17

    • Biologics, Proteins, Vaccines
      India is an Emerging Hub  For Low-cost Vaccines

      India is an Emerging Hub For Low-cost Vaccines

      Improvising basic vaccines to enhance stability, efficacy and compliance
      S. Harachand, Contributing Editor 11.07.17

    • Biologics, Proteins, Vaccines
      Flu Season is Upon Us

      Flu Season is Upon Us

      My chance and capricious Monday afternoon run-in with antiscience nonsense
      Ben Locwin, Contributing Editor 11.07.17


    • Biologics, Proteins, Vaccines
      Trends in New Technologies & Budgets

      Trends in New Technologies & Budgets

      Budget increases in biopharmaceutical industry indicate future growth
      Eric S. Langer, BioPlan Associates 06.06.17

    • Biologics, Proteins, Vaccines

      Biomanufacturing Trends and Outlook 2017: Where Is It All Going?

      A look at the technological advances permeating (bio)pharma manufacturing
      Ben Locwin, Contributing Editor 04.20.17

    • Biologics, Proteins, Vaccines
      CMOs Hiring Constraints:  Cell Therapy Manufacturing Expecting Future Challenges

      CMOs Hiring Constraints: Cell Therapy Manufacturing Expecting Future Challenges

      Technically trained staff needed to run complex manufacturing platforms, automation
      Eric S. Langer, BioPlan Associates 03.07.17


    • Biologics, Proteins, Vaccines

      Year-End Trends in Biopharma Contract Manufacturing

      Budgets are flattening, but some CMOs are well positioned for growth
      Eric S. Langer, BioPlan Associates 11.09.16

    • Biologics, Proteins, Vaccines | cGMP Manufacture | GMPs/GCPs | Preclinical Outsourcing | Process Development | Risk Management

      Getting to Yes

      The critical attributes CMOs need to demonstrate to win business
      Eric S. Langer, BioPlan Associates 07.14.15

    • Biologics, Proteins, Vaccines | Biosimilars | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Logistics | Lyophilization | Methods Development | Process Development | QA/QC | Serialization | Supply Chain | Validation

      CMOs Facing Significant Capacity Constraints

      Downstream purification creating chronic problems
      Eric S. Langer, BioPlan Associates 06.02.15

    Trending
    • Catalent Acquires Delphi Genetics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • WuXi AppTec Completes OXGENE Acquisition
    Breaking News
    • Amgen to Acquire Five Prime Therapeutics for $1.9B
    • Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    • CureVac, Novartis Ink COVID Vax Mfg. Pact
    • Innoforce and dMed Enter Development Collaboration
    • Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Statins May Contribute to Vascular Calcification by Inhibiting Vitamin K-Dependent Proteins
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Maroon Group Acquires Cary Company's Raw Materials, Specialty Chemicals Distribution Business
    Matt Fogel Named Mule-Hide's Territory Manager – Southern Virginia
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    EchoNous Expands Its Kosmos Hardware Platform
    Medtronic Begins Trial to Assess Novel Ablation Tech to Treat AFib
    Europe's Cross-Border Medtech Deal Activity Rises in Q4 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Amgen to Acquire Five Prime Therapeutics for $1.9B
    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    CureVac, Novartis Ink COVID Vax Mfg. Pact
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Estée Lauder Establishes Equity and Engagement Center of Excellence
    L'Oreal On How It Will Shape Beauty's Future at Today's Transparency Summit
    C.O. Bigelow Earns Praise as NYC's Oldest Family-Run Apothecary
    Happi

    Latest Breaking News From Happi

    Avon Launches Vegan Skin Care Line
    Inolex Appoints VP Marketing
    Decorté Launches AI Diagnostics in US
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Springfield Solutions highlights digital label embellishments
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Bioventus Appoints Managing Director, China and Asia Pacific
    Full-Year Sales Down 12 Percent at Zimmer Biomet
    Lincotek Medical Expands Coatings and Additive Capacity
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login